The susceptibilities of 12 strains of enterococci and 10 strains of Listeria monocytogenes to N-formimidoyl thienamycin were determined by a standard broth dilution method. Minimal inhibitory concentrations for L. monocytogenes strains were less than 0.25 ,ug/ml. As a group, strains of Streptococcus faecium were less susceptible than Streptococcus faecalis strains, but even for the latter, the minimal inhibitory concentrations were slightly greater than those previously reported. Minimal bactericidal concentrations against all organisms were manyfold higher than the corresponding inhibitory concentrations. In time-kill studies, combinations of N-formimidoyl thienamycin with gentamicin were synergistic against (or they completely sterilized cultures of) all of the enterococcal strains and nine of 10 strains of L. monocytogenes. The magnitude of killing by the combinations was comparable to that previously observed with penicillin-gentamicin combinations. N-Formimidoyl thienamycin-tobramycin combinations were synergistic against those strains of S. faecalis and L. monocytogenes tested, but not against those of S. faecium.
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Initial studies have shown that the new ,Blactam antibiotic thienamycin and its more stable N-formimidoyl derivative are active against a wide variety of bacteria, including enterococci. When tested by microtiter, agar dilution, and disk diffusion techniques, the majority of enterococcal isolates are inhibited by N-formimidoyl thienamycin at concentrations of less than 2 ,Ag/ ml (5, 8) . Published data on the miniimal bactericidal concentration of N-formimidoyl thienamycin for enterococci are not presently available.
Currently employed antibiotics are only bacteriostatic against enterococci at concentrations readily achievable in the serum, and successful therapy of enterococcal endocarditis usually requires the addition of an aminoglycoside to penicillin, ampicillin, or vancomycin for synergistic killing (14) . There are also significant differences between the inhibitory and bactericidal concentrations of penicillin or ampicillin for Listeria monocytogenes (11, 19) . Here too, enhanced killing by the addition of an aminoglycoside to cell wall-active agents has been demonstrated both in vitro (11, 19) and in animal models (2, 12, 16) , but the clinical benefits of such combinations are less clear (13) .
In the present study, we examined the susceptibilities to N-formimidoyl thienamycin ofStreptococcus faecalis, Streptococcus faecium, and L. monocytogenes by a broth dilution method and evaluated combinations of this antibiotic with an aminoglycoside for synergistic activity against these organisms.
MATERIALS AND METHODS
The organisms used were clinical isolates from the Massachusetts General Hospital, except for L. monocytogenes strains 6 through 10 which had been obtained from the Centers for Disease Control, Atlanta, Ga. The isolates had been identified as previously reported (3, 11) and stored at -70°C. After thawing, they were maintained on brucella agar plates with 5% horse blood (GIBCO Diagnostics, Madison, Wis.).
N-Formimidoyl thienamycin (MK0787) was provided by the Merck Institute for Therapeutic Research, Rahway, N.J. The concentration of the drug in a prepared solution was confirmed in our laboratory by a differential spectrophotometric assay, as described previously for the parent compound (4 gism was observed when the inoculum was decreased to 105 colony-forming units per ml (Table 2) . Combinations of gentamicin with Nformimidoyl thienamycin at 4 ,ug/ml resulted in a 2-log10 enhancement of killing at 4 h in five strains, but at this concentration the 8-lactam alone achieved a 10-fold greater kill than at the higher concentration (Table 3) , diminishing the magnitude of the difference between killing by the single agent and the combination observed at 24 h. The results of a representative experi- 'The combination led to sterilization of the culture within 4 h. N-Formimidoyl thienamycin-gentamicin synergism was noted in nine strains of L. monocytogenes with a low concentration of the former drug, and in eight strains with the drug concentration at 10 ,ug/ml (Table 4) . For both isolates which were not killed synergistically at the higher concentrations, log1o kills by the combinations were as great as those found for strains in which synergism was demonstrated. Lack of synergism, therefore, was attributable to the relative efficiency of killing by N-formimidoyl thienamycin alone. In contrast to the situation with S. faecalis, mean 24-h cell kills at the two F-TNIEN i/ml concentrations of the f,-lactam were identical (Table 3) . N-formimidoyl thienamycin-tobra-F-THIEN 4/ml mycin synergism was found in the three strains tested. 
DISCUSSION
Enterococci. Although only six strains of each species were examined, it was apparent that as a group, S. faecium strains were less susceptible to N-formimidoyl thienamycin than were S. faecalis strains. Such species differences may account in part for the wide range in previously reported MICs for enterococci (8) 260, 1980) .
As is the case with penicillin, MBCs of Nformimidoyl thienamycin were severalfold higher than its corresponding MICs. This finding is not unexpected since defective killing of enterococci by cell wall-active agents most likely reflects an inherent property of the organisms (7) . Despite the fact that these strains of S. faecalis are tolerant to both N-formimidoyl thienamycin and penicillin, the former drug at concentrations of 4 tig/ml resulted in a 30-fold greater killing at 24 h than did penicillin at 6,ug/ ml in time-kill studies previously done by a similar method (10) . However, because of less efficient killing at increasing antibiotic concentrations, which has been termed the "paradoxic effect" (1), such comparisons may not be entirely valid.
Interestingly, the magnitude of killing by synergistic combinations of N-formimidoyl thienamycin and gentamicin is similar to that seen with penicillin-gentamicin combinations (10) . Nevertheless, caution must be exercised in predicting clinical utility from these studies. For example, whereas synergism against enterococci can be demonstrated for nafcillin-gentamicin combinations in broth, the addition of serum, to which the former drug is highly bound, negates this effect, suggesting that such combinations might fail in the treatment of endocarditis (3). Although we have not examined the effect of serum on the activity of N-formimidoyl thienamycin-gentamicin combinations in this laboratory, preliminary work suggests that N-formimidoyl thienamycin is not highly protein bound (H. Kropp, personal communication) .
Recently, the presence of an aminoglycoside 6'-acetyltransferase has been discovered in S.
faecium, which provides an explanation for the failure of penicillin-tobramycin synergy in this species (18) . On the basis of our present studies, we propose that N-formimidoyl thienamycin-tobramycin combinations would fail in this situation as well.
L. monocytogenes. In vitro synergism between penicillin or ampicillin and gentamicin against many strains of this organism is well recognized (9, 11, 19) . The mean reduction in numbers of viable cells which we have observed with combinations of N-formimidoyl thienamycin and gentamicin is equal to that previously seen with penicillin-gentamicin combinations (11) . Combinations of the new f8-lactam with tobramycin also demonstrated synergistic killing, as might be expected on the basis ofreported penicillin-tobramycin synergism (15) .
While the potential benefits of synergistic therapy of Listeria infections are supported by data from animal models (2, 16) and seem particularly attractive since many patients with such infections have defects in host defense mechanisms, successful therapy of human infections with a single agent has been well documented (13) . Whether N-formimidoyl thienamycin, alone or in combination with an aminoglycoside, will prove equal or superior to current regimens for the treatment of infections due to L. monocytogenes in humans remains to be determined, especially in light of the fact that the extent of penetration of this drug into the cerebrospinal fluid is at present unknown, and because of the wide range in the MBCs of Nformimidoyl thienamycin against these organisms.
